Centres de Production et de Contrôle de Produits de Thérapie Génique

La production et le contrôle de produits de biothérapie par des laboratoires et sociétés observant des pratiques satisfaisantes aux exigences des agences réglementaires (jusqu'au stade "Bonnes Pratiques de Fabrication "BPF") est indispensable pour accéder aux essais cliniques.

Voici un certain nombre d'installations capables de fabriquer des produits de biothérapies cliniques et pré-cliniques de qualité, y compris des plasmides, des oligonucléotides et des vecteurs viraux. Vous y trouverez aussi une sélection d'installations capables de mener à bien les séries de tests nécessaires pour répondre aux normes de sécurité et demandés par les organismes de régulation.

bluebird bio

Bluebird Logo Website

bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company’s novel approach uses stem cells harvested from the patient’s bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to the patient. bluebird bio’s approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell anemia. Led by a world-class team, bluebird bio is privately-held and backed by top-tier life sciences investors, including Third Rock Ventures, TVM Capital, ARCH Venture Partners, Forbion Capital Partners, Easton Capital and Genzyme Ventures. Its operations are located in Cambridge, Mass. and Paris, France.

Gene Therapy, The Time is Now

Over the last few years, a small but growing number of gene therapy trials have yielded increasingly promising results. bluebird bio’s proprietary lentiviral technology is designed to deliver corrective genes to the patient’s own bone marrow cells, providing a possible one-time effective therapy, a treatment approach that represents a true paradigm shift in the treatment of genetic diseases. bluebird bio has candidates in clinical development for the treatment of CCALD, a severe neurodegenerative disorder, and beta-thalassemia, one of the most prevalent human genetic disorders. Both of these programs have shown promising early results in human trials to date with stabilization of their respective diseases. Results from the CCALD program were published in the November 2009 issue of Science.

Click here to visit the bluebird bio site


Aldevron Almac Amsterdam Molecular Technologies
Angel Bio Avecia Biologics Avigen
Bio Products Laboratory Biogenova Bioprocessing Technology Institute
Bioreliance Ltd Biotec Distribution Wales Limited Boehringer Ingelheim RCV
Cancer Research UK CellGenix Celltec
Clinical Biomanufacturing Facility, Oxford Cobra Biomanufacturing Covance
Eden Biodesign Ltd Emergent Product Development UK Limited EUFETS AG
Eurogentec s.a. Gene Therpay Centre, Huddinge Hospital, Karolinska Institutet GeneArt/Genovac
Genethon Génosafe Genzyme Limited
VirXsys Henogen Introgen
Invitrogen/Bioreliance Lentigen Lonza Biologics
Microsafe BV Molmed NHSBT, Clinical Biotechnology Centre
Npil Pharmaceuticals (UK) Limited Omnia Biologics, Inc. PacificGMP
Plasmid Factory Polyplus-Transfection Powell Gene Therapy Centre, University of Florida
Protherics UK Limited Qbiogene Qiagen
Quintiles Limited Rentschler Biotechnologie Targeted Genetics
Texcell, a Pasteur Institute Co The Goldyne Saved Institute of Gene and therapy, Jerusalem, Israel Ucb Celltech
Vector Biolabs Vecura